12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Tuning the Antigen Density Requirement for CAR T-cell Activity.

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Insufficient reactivity against cells with low antigen density has emerged as an important cause of chimeric antigen receptor (CAR) T-cell resistance. Little is known about factors that modulate the threshold for antigen recognition. We demonstrate that CD19 CAR activity is dependent upon antigen density and that the CAR construct in axicabtagene ciloleucel (CD19-CD28ζ) outperforms that in tisagenlecleucel (CD19-4-1BBζ) against antigen-low tumors. Enhancing signal strength by including additional immunoreceptor tyrosine-based activation motifs (ITAM) in the CAR enables recognition of low-antigen-density cells, whereas ITAM deletions blunt signal and increase the antigen density threshold. Furthermore, replacement of the CD8 hinge-transmembrane (H/T) region of a 4-1BBζ CAR with a CD28-H/T lowers the threshold for CAR reactivity despite identical signaling molecules. CARs incorporating a CD28-H/T demonstrate a more stable and efficient immunologic synapse. Precise design of CARs can tune the threshold for antigen recognition and endow 4-1BBζ-CARs with enhanced capacity to recognize antigen-low targets while retaining a superior capacity for persistence. SIGNIFICANCE: Optimal CAR T-cell activity is dependent on antigen density, which is variable in many cancers, including lymphoma and solid tumors. CD28ζ-CARs outperform 4-1BBζ-CARs when antigen density is low. However, 4-1BBζ-CARs can be reengineered to enhance activity against low-antigen-density tumors while maintaining their unique capacity for persistence.This article is highlighted in the In This Issue feature, p. 627.

          Related collections

          Author and article information

          Journal
          Cancer Discov
          Cancer discovery
          American Association for Cancer Research (AACR)
          2159-8290
          2159-8274
          May 2020
          : 10
          : 5
          Affiliations
          [1 ] Department of Pediatrics, Stanford University School of Medicine, Stanford, California.
          [2 ] Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
          [3 ] Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, California.
          [4 ] Biophysics Program, Stanford University, Stanford, California.
          [5 ] Department of Bioengineering, Stanford University School of Medicine, Stanford, California.
          [6 ] Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
          [7 ] KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.
          [8 ] Department of Chemical Engineering, Stanford University, Stanford, California.
          [9 ] Cardiovascular Institute, Stanford University School of Medicine, Stanford, California.
          [10 ] The Howard Hughes Medical Institute, University of California, San Francisco, San Francisco, California.
          [11 ] Department of Pediatrics, Stanford University School of Medicine, Stanford, California. cmackall@stanford.edu.
          [12 ] Department of Medicine, Stanford University School of Medicine, Stanford, California.
          Article
          2159-8290.CD-19-0945
          10.1158/2159-8290.CD-19-0945
          32193224
          5276b5c8-f004-43e5-9b0e-4b3594031bfa
          History

          Comments

          Comment on this article